Opinion|Videos|August 6, 2024
Management Strategies for BTKi-Related CVAEs in CLL
Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is your general approach in managing newly acquired or worsening HTN or treatment-related AFib in patients receiving treatment with BTKi inhibitors?
- How do you approach treatment management in these clinical scenarios?
- When do you involve cardiology?
- When may alternative therapy be warranted?
Advertisement
Related to this article
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
5